Summary
The trial of a new drug, bexobrutideg, shows promising results for chronic lymphocytic leukemia patients previously treated extensively, with an 80.9% response rate observed.
Source: Hoodline
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
